# Severe Malaria Due to Plasmodium vivax With Pulmonary Involvement: A Case Report

**Authors:** Teresa Valido, Ana Goncalves, Marta Sanches, Teresa Costa Silva, Carlos Pereira

PMC · DOI: 10.7759/cureus.102880 · 2026-02-03

## TL;DR

A woman from India developed severe malaria caused by Plasmodium vivax after traveling to Portugal, requiring ICU care and treatment.

## Contribution

This case report highlights the potential severity of Plasmodium vivax malaria, including pulmonary involvement.

## Key findings

- The patient had severe anemia, thrombocytopenia, and pulmonary involvement due to P. vivax.
- Treatment with artemether-lumefantrine and doxycycline led to rapid clinical improvement and clearance of parasitemia.
- The case emphasizes the importance of considering P. vivax in patients with relevant travel history.

## Abstract

Malaria is a disease caused by Plasmodium parasites and spread through the bites of female Anopheles mosquitoes. Although Plasmodium falciparum remains the primary species causing severe malaria, Plasmodium vivax is increasingly recognized, and its latent forms can reactivate months to years after exposure. A 46-year-old woman from India, who had traveled to Portugal for six months, was admitted to the emergency department with asthenia and fatigue for three days. On examination, she was febrile and hypoxemic. Additional evaluation revealed severe anemia, thrombocytopenia, and extensive areas of ground-glass opacification on chest tomography. She was admitted to the ICU and required high-flow oxygen therapy. During further evaluation, P. vivax was identified, with a parasitemia of 50% and a parasite density of 8,645 parasites/µL. Due to the unavailability of IV artesunate, treatment was initiated with artemether-lumefantrine and doxycycline, resulting in progressive improvement and successful oxygen weaning. By the third day of treatment, parasitemia had cleared. This case underscores the need for high clinical suspicion for P. vivax malaria in patients with relevant epidemiological exposure.

## Linked entities

- **Chemicals:** doxycycline (PubChem CID 54671203)
- **Diseases:** malaria (MONDO:0005136), thrombocytopenia (MONDO:0002049)
- **Species:** Plasmodium vivax (taxon 5855), Anopheles (taxon 7164)

## Full-text entities

- **Genes:** HP (haptoglobin) [NCBI Gene 3240] {aka HP2ALPHA2, HPA1S}, G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}
- **Diseases:** acute pulmonary edema (MESH:D011654), acute lung injury (MESH:D055371), microcytosis (OMIM:616959), respiratory complications (MESH:D012140), cerebral involvement (MESH:D002547), Pulmonary Involvement (MESH:C566343), disease (MESH:D004194), shock (MESH:D012769), inflammation (MESH:D007249), hepatic and renal dysfunction (MESH:D008107), vasculitic condition (MESH:D020763), hemolytic (MESH:D006461), hypoxemia (MESH:D000860), ARDS (MESH:D012128), seizures (MESH:D012640), acute kidney injury (MESH:D058186), vitamin B12 deficiency (MESH:D014806), chest pain (MESH:D002637), jaundice (MESH:D007565), fatigue (MESH:D005221), autoimmune (MESH:D001327), multi-organ dysfunction (MESH:D009102), febrile (MESH:D000071072), infiltrates (MESH:D017254), tachycardia (MESH:D013610), bleeding (MESH:D006470), Respiratory dysfunction (MESH:D012131), P. vivax infection (MESH:D016780), hematemesis (MESH:D006396), cerebral malaria (MESH:D016779), metabolic acidosis (MESH:D000138), dizziness (MESH:D004244), dehydrated (MESH:D003681), parasitemia (MESH:D018512), cough (MESH:D003371), thrombocytopenia (MESH:D013921), coagulopathy (MESH:D001778), hypoglycemia (MESH:D007003), infection (MESH:D007239), G6PD deficiency (MESH:D005955), hepatomegaly (MESH:D006529), melena (MESH:D008551), reduced consciousness (MESH:D003244), hypertension (MESH:D006973), hypothyroidism (MESH:D007037), microvascular dysfunction (MESH:D017566), anemia (MESH:D000740), severe (MESH:D045169), infectious diseases (MESH:D003141), Coma (MESH:D003128), Malaria (MESH:D008288), asthenia (MESH:D001247), prostration (MESH:D006359), systemic (MESH:D015619), liver or renal impairment (MESH:D017093), hemolytic anemia (MESH:D000743), interstitial pneumonitis (MESH:D017563)
- **Chemicals:** bilirubin (MESH:D001663), oxygen (MESH:D010100), doxycycline (MESH:D004318), artesunate (MESH:D000077332), artemisinin (MESH:C031327), iron (MESH:D007501), methylprednisolone (MESH:D008775), cinchona alkaloids (MESH:D002930), urea (MESH:D014508), levothyroxine (MESH:D013974), red blood cell concentrate (-), folate (MESH:D005492), creatinine (MESH:D003404), azilsartan (MESH:C521273), artemether-lumefantrine (MESH:D000077611), cyanocobalamin (MESH:D014805), primaquine (MESH:D011319)
- **Species:** Plasmodium cf. vivax (species) [taxon 943110], Anopheles (series) [taxon 44484], Homo sapiens (human, species) [taxon 9606], Plasmodium falciparum (malaria parasite P. falciparum, species) [taxon 5833], Plasmodium vivax (malaria parasite P. vivax, species) [taxon 5855]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12961722/full.md

---
Source: https://tomesphere.com/paper/PMC12961722